循环游离细菌DNA作为晚期胰腺癌治疗反应监测的新型生物标志物
本研究评估了循环游离细菌DNA(cfbDNA)动态变化对接受全身化疗的晚期胰腺癌(aPDAC)患者预后的预测价值。探索队列纳入13例接受mFOLFIRINOX(FFX)治疗的患者,并在NEOLAP-AIO-PAK-0113试验的47例局部晚期胰腺癌患者样本中验证。结果显示cfbDNA下降与FFX治疗患者更好的无进展生存期(PFS)和总生存期(OS)相关,但在继续接受吉西他滨联合白蛋白结合型紫杉醇(GnP)治疗的患者中,cfbDNA下降与更短的PFS和OS相关。
要点
- cfbDNA动态变化可能作为aPDAC患者化疗反应监测的血液生物标志物。
- FFX治疗中cfbDNA下降与改善的PFS和OS相关,而GnP治疗中下降与更差生存相关。
- cfbDNA的预测影响具有治疗依赖性,提示宿主-微生物-肿瘤相互作用,需前瞻性验证。
核心结论
- cfbDNA动态变化可能作为监测aPDAC治疗反应的血液生物标志物,其预测影响具有治疗依赖性。
研究设计与样本
- 探索性队列分析13例接受mFOLFIRINOX治疗的aPDAC患者血清cfbDNA动态,并在NEOLAP-AIO-PAK-0113试验的47例局部晚期胰腺癌患者样本中验证。
主要发现
- 探索队列中,FFX治疗期间cfbDNA下降与改善的PFS(14.3 vs. 2.9个月;p < 0.001)和OS(23.2 vs. 8.4个月;p = 0.006)相关。
- 探索队列中,cfbDNA相等或增加与更差OS相关(单变量分析HR 7.74;95% CI 1.38-43.24;p = 0.020;调整CA-19-9组后HR 11.75;95% CI 1.87-73.85;p = 0.009)。
- NEOLAP队列中,FFX治疗患者cfbDNA下降与改善的PFS(12.4 vs. 8.7个月,p = 0.003)和OS(39.8 vs. 14.7个月,p = 0.001)相关。
- NEOLAP队列中,继续GnP治疗患者cfbDNA下降与更短的PFS(6.2 vs. 11.5个月,p < 0.001)和OS(12.9 vs. 18.8个月,p = 0.013)相关。
临床怎么用
- cfbDNA动态变化可能辅助临床决策,但需考虑治疗方案特异性,目前尚需前瞻性验证。
局限性
- 探索性队列样本量小(13例),验证队列为局部晚期胰腺癌患者,需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Monitoring therapy response in pancreatic cancer (PDAC) remains challenging. The microbiome affects therapy efficacy, but its role in response prediction is unclear. We assessed whether changes in circulating free bacterial DNA (cfbDNA) levels predict outcome of advanced PDAC (aPDAC) patients treated with systemic chemotherapy. PATIENTS AND METHODS: We analyzed the prognostic impact of serum cfbDNA dynamics of 13 patients with aPDAC receiving mFOLFIRINOX (FFX) before treatment initiation and after two chemotherapy cycles. We validated the findings in the samples of 47 patients with locally advanced pancreatic cancer from the NEOLAP-AIO-PAK-0113 trial. RESULTS: Decreased cfbDNA during FFX treatment was associated with improved PFS (14.3 vs. 2.9 months; p < 0.001) and OS (23.2 vs. 8.4 months; p = 0.006) in the exploratory cohort. Equal or increased cfbDNA was associated with inferior OS in univariate analyses (HR, 7.74; 95% CI, 1.38-43.24; p = 0.020) and a model adjusted for CA-19-9 group (HR, 11.75; 95% CI, 1.87-73.85; p = 0.009). In the NEOLAP cohort, decreased cfbDNA was associated with improved PFS (12.4 vs. 8.7 months, p = 0.003) and OS (39.8 vs. 14.7 months, p = 0.001) in FFX treated patients, whereas in patients continuing on gemcitabine plus nab-paclitaxel (GnP), decreased cfbDNA was associated with shorter PFS (6.2 vs. 11.5 months, p < 0.001) and OS (12.9 vs. 18.8 months, p = 0.013). CONCLUSIONS: cfbDNA dynamics may serve as blood-based biomarker for monitoring therapy response in aPDAC. Its treatment-dependent predictive impact may inform clinical decisions. These findings suggest therapy-specific host-microbiome-tumor interactions and warrant prospective validation. CLINICAL TRIAL NUMBER: NCT02125136.
引用
- Surendran SA, Guenther M, Nemati N, et al. Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. Eur J Cancer. 2026. PMID: 42743886. doi:10.1016/j.ejca.2026.117040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。